Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: An NCIC CTG MA.17 sub-study

Kishor M. Wasan, Paul E. Goss, P. Haydn Pritchard, Lois Shepherd, Dongsheng Tu, James N. Ingle

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

To evaluate changes in serum lipid parameters (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and lipoprotein(a) [Lp(a)]), in postmenopausal women receiving letrozole after tamoxifen therapy. MA.17L is a sub-study of MA.17, a double-blind, placebo-controlled trial of extended adjuvant letrozole. Eligible postmenopausal women were non-hyperlipidemic and not on lipid-lowering drugs. This analysis considers the 183 patients on the letrozole arm. Lipid parameters evaluated at baseline, 6 months, 12 months, and yearly thereafter until completion of 5 years of letrozole. The median duration of letrozole treatment was 5.0 years with a range from 0.03 to 6.05 years. After 5 year tamoxifen, patients on letrozole experienced significant increases from baseline in total cholesterol, LDL cholesterol, and Lp(a) at all study time points but no statistically significant changes in triglycerides. Specifically, a statistically significant increase was found at 60 months in total cholesterol [mean percentage change from baseline (PC) 5.27; p = 0.003], HDL cholesterol (mean PC 6.75; p = 0.003), LDL cholesterol (mean PC 10.02; p = 0.001), Lp(a) (mean PC 105.95; p < 0.0001). 103 (56 %) women in the study had clinically significantly elevated levels of Lp(a) (106 % above baseline) after 5 years of therapy. The results were similar after excluding the 21 % of patients who had ever received anti-lipid treatment. Significant increases in total cholesterol, HDL cholesterol, LDL cholesterol, and, most notably, Lp(a) in postmenopausal women were observed following 5 years of adjuvant letrozole treatment and after 5 years of tamoxifen therapy and such patients should have monitoring of their lipid levels in clinical practice.

Original languageEnglish (US)
Pages (from-to)769-776
Number of pages8
JournalBreast Cancer Research and Treatment
Volume136
Issue number3
DOIs
StatePublished - Dec 2012

Fingerprint

letrozole
Tamoxifen
Lipoprotein(a)
Lipids
LDL Cholesterol
Cholesterol
HDL Cholesterol
Therapeutics

Keywords

  • 5-year follow-up
  • Letrozole
  • Postmenopausal women
  • Primary breast cancer
  • Serum lipids
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen : An NCIC CTG MA.17 sub-study. / Wasan, Kishor M.; Goss, Paul E.; Pritchard, P. Haydn; Shepherd, Lois; Tu, Dongsheng; Ingle, James N.

In: Breast Cancer Research and Treatment, Vol. 136, No. 3, 12.2012, p. 769-776.

Research output: Contribution to journalArticle

Wasan, Kishor M. ; Goss, Paul E. ; Pritchard, P. Haydn ; Shepherd, Lois ; Tu, Dongsheng ; Ingle, James N. / Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen : An NCIC CTG MA.17 sub-study. In: Breast Cancer Research and Treatment. 2012 ; Vol. 136, No. 3. pp. 769-776.
@article{484261a7c2d746dea734c4b5bfff00c8,
title = "Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: An NCIC CTG MA.17 sub-study",
abstract = "To evaluate changes in serum lipid parameters (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and lipoprotein(a) [Lp(a)]), in postmenopausal women receiving letrozole after tamoxifen therapy. MA.17L is a sub-study of MA.17, a double-blind, placebo-controlled trial of extended adjuvant letrozole. Eligible postmenopausal women were non-hyperlipidemic and not on lipid-lowering drugs. This analysis considers the 183 patients on the letrozole arm. Lipid parameters evaluated at baseline, 6 months, 12 months, and yearly thereafter until completion of 5 years of letrozole. The median duration of letrozole treatment was 5.0 years with a range from 0.03 to 6.05 years. After 5 year tamoxifen, patients on letrozole experienced significant increases from baseline in total cholesterol, LDL cholesterol, and Lp(a) at all study time points but no statistically significant changes in triglycerides. Specifically, a statistically significant increase was found at 60 months in total cholesterol [mean percentage change from baseline (PC) 5.27; p = 0.003], HDL cholesterol (mean PC 6.75; p = 0.003), LDL cholesterol (mean PC 10.02; p = 0.001), Lp(a) (mean PC 105.95; p < 0.0001). 103 (56 {\%}) women in the study had clinically significantly elevated levels of Lp(a) (106 {\%} above baseline) after 5 years of therapy. The results were similar after excluding the 21 {\%} of patients who had ever received anti-lipid treatment. Significant increases in total cholesterol, HDL cholesterol, LDL cholesterol, and, most notably, Lp(a) in postmenopausal women were observed following 5 years of adjuvant letrozole treatment and after 5 years of tamoxifen therapy and such patients should have monitoring of their lipid levels in clinical practice.",
keywords = "5-year follow-up, Letrozole, Postmenopausal women, Primary breast cancer, Serum lipids, Tamoxifen",
author = "Wasan, {Kishor M.} and Goss, {Paul E.} and Pritchard, {P. Haydn} and Lois Shepherd and Dongsheng Tu and Ingle, {James N.}",
year = "2012",
month = "12",
doi = "10.1007/s10549-012-2294-z",
language = "English (US)",
volume = "136",
pages = "769--776",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen

T2 - An NCIC CTG MA.17 sub-study

AU - Wasan, Kishor M.

AU - Goss, Paul E.

AU - Pritchard, P. Haydn

AU - Shepherd, Lois

AU - Tu, Dongsheng

AU - Ingle, James N.

PY - 2012/12

Y1 - 2012/12

N2 - To evaluate changes in serum lipid parameters (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and lipoprotein(a) [Lp(a)]), in postmenopausal women receiving letrozole after tamoxifen therapy. MA.17L is a sub-study of MA.17, a double-blind, placebo-controlled trial of extended adjuvant letrozole. Eligible postmenopausal women were non-hyperlipidemic and not on lipid-lowering drugs. This analysis considers the 183 patients on the letrozole arm. Lipid parameters evaluated at baseline, 6 months, 12 months, and yearly thereafter until completion of 5 years of letrozole. The median duration of letrozole treatment was 5.0 years with a range from 0.03 to 6.05 years. After 5 year tamoxifen, patients on letrozole experienced significant increases from baseline in total cholesterol, LDL cholesterol, and Lp(a) at all study time points but no statistically significant changes in triglycerides. Specifically, a statistically significant increase was found at 60 months in total cholesterol [mean percentage change from baseline (PC) 5.27; p = 0.003], HDL cholesterol (mean PC 6.75; p = 0.003), LDL cholesterol (mean PC 10.02; p = 0.001), Lp(a) (mean PC 105.95; p < 0.0001). 103 (56 %) women in the study had clinically significantly elevated levels of Lp(a) (106 % above baseline) after 5 years of therapy. The results were similar after excluding the 21 % of patients who had ever received anti-lipid treatment. Significant increases in total cholesterol, HDL cholesterol, LDL cholesterol, and, most notably, Lp(a) in postmenopausal women were observed following 5 years of adjuvant letrozole treatment and after 5 years of tamoxifen therapy and such patients should have monitoring of their lipid levels in clinical practice.

AB - To evaluate changes in serum lipid parameters (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and lipoprotein(a) [Lp(a)]), in postmenopausal women receiving letrozole after tamoxifen therapy. MA.17L is a sub-study of MA.17, a double-blind, placebo-controlled trial of extended adjuvant letrozole. Eligible postmenopausal women were non-hyperlipidemic and not on lipid-lowering drugs. This analysis considers the 183 patients on the letrozole arm. Lipid parameters evaluated at baseline, 6 months, 12 months, and yearly thereafter until completion of 5 years of letrozole. The median duration of letrozole treatment was 5.0 years with a range from 0.03 to 6.05 years. After 5 year tamoxifen, patients on letrozole experienced significant increases from baseline in total cholesterol, LDL cholesterol, and Lp(a) at all study time points but no statistically significant changes in triglycerides. Specifically, a statistically significant increase was found at 60 months in total cholesterol [mean percentage change from baseline (PC) 5.27; p = 0.003], HDL cholesterol (mean PC 6.75; p = 0.003), LDL cholesterol (mean PC 10.02; p = 0.001), Lp(a) (mean PC 105.95; p < 0.0001). 103 (56 %) women in the study had clinically significantly elevated levels of Lp(a) (106 % above baseline) after 5 years of therapy. The results were similar after excluding the 21 % of patients who had ever received anti-lipid treatment. Significant increases in total cholesterol, HDL cholesterol, LDL cholesterol, and, most notably, Lp(a) in postmenopausal women were observed following 5 years of adjuvant letrozole treatment and after 5 years of tamoxifen therapy and such patients should have monitoring of their lipid levels in clinical practice.

KW - 5-year follow-up

KW - Letrozole

KW - Postmenopausal women

KW - Primary breast cancer

KW - Serum lipids

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84878758037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878758037&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2294-z

DO - 10.1007/s10549-012-2294-z

M3 - Article

C2 - 23089983

AN - SCOPUS:84878758037

VL - 136

SP - 769

EP - 776

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -